The potential value ofthe antifolate methotrexate (N1O-methylaminopterin) in the treatment of rheumatoid arthritis (RA) was first recognised in 1951. ' The low dose drug administration in divided doses 12 hours apart was developed for the treatment of patients with psoriasis, based on properties of psoriatic epithelial cells and the biological action of methotrexate on these cells.2 To date its mode of action has not been well established. 3 It is generally believed that low dose weekly pulses of methotrexate are not markedly immunosuppressive. This is based on the inconsistency of in vitro and in vivo observed changes in immune variables.3 ' During treatment with low dose methotrexate, however, complications suggestive of immunosuppression may occur, such as varicella zoster, Pneumocstts carinni, and fungal infections. 5 Only with a high dose of methotrexate, comparable with that used in patients with malignancies, does a decrease in surface DR expression on peripheral T lymphocytes occur.6 As activated T lymphocytes-bearing Ia antigens-have a role in the pathogenesis of rheumatoid arthritis7 this is an interesting finding.
Biochemically These prospective studies differ not only in study design (uncontrolled or double blind, placebo controlled), but also in study duration, relative dose of folic or folinic acid, and interval between supplementation and weekly pulse methotrexate. Except for Stewart's study the number of studied patients was low (seven to 32) and the duration of the study short (four to 48 weeks). Unfortunately, the Cl index was not measured in any of these studies.
Hanrahan and Buckley's double blind, crossover study comparing folinic acid (leucovorin) with placebo did not show any decrease in toxic reactions in patients receiving folinic acid.'3 Is Tishler's unblinded case controlled study '4 showed folinic acid to be effective in preventing nausea caused by low dose methotrexate treatment in RA. This benefit was overshadowed, however, by increased rheumatic disease activity in all patients. Delaying folinic acid treatment for four to six hours after methotrexate administration should reduce competition for methotrexate uptake for entry into the cell. The extent of elimination of the uptake of methotrexate by folinic acid will be dependent on the relative dose of both drugs. The (14) A (7) 9-6 Folinic acid, 15 mg/day for 3 days, Diminished Diminished starting 4-6 h after MTX *A=prospective, open study; B=randomised, placebo controlled, double blind, crossover study.
Buckley may explain the exacerbation of the rheumatic disease in the first study.
As folinic acid is a stable reduced folate that bypasses dihydrofolate reductase, doses and intervals of administration may be more critical than with the fully oxidised form of the vitamin, folic acid.
Both studies dealing with concurrent use of folic acid and methotrexate reported a significant decrease in methotrexate adverse effects, whereas the clinical efficacy of methotrexate seemed to be unchanged. One study was double blind, placebo controlled crossover during 24 weeks'6 and the other study was uncontrolled during 41 We conclude that as long as the mechanism of action-folate antagonism or otherwise-of methotrexate in RA is not known the beneficial effect of folate supplementation may still be considered to be a result of the relative reduction of the dose of methotrexate. As only minor side effects are reduced (there are no data about major complications, such as cytopenia and opportunistic infections) a reduction in the dose of methotrexate makes more sense than oral folate supplementation.
